Inhibition of Renalase Drives Tumour Rejection by Promoting T Cell Activation

Background: Although programmed cell death protein 1 (PD-1) inhibitors have re-volutionised treatment for advanced melanoma, not all patients respond. We previously showed that inhibition of the flavoprotein renalase (RNLS) in preclinical melanoma models decreases tumour growth. We hypothesised that RNLS inhibition promotes tumour rejection by effects on the tumour microenvironment (TME). Methods: We used two distinct murine melanoma models, studied in RNLS knockout (KO) or wild-type (WT) mice. WT mice were treated with the anti-RNLS antibody, m28, with or without anti-PD-1. 10X single-cell RNA-sequencing was used to identify transcriptional dif-ferences between treatment groups, and tumour cell content was interrogated by flow cytome-try. Samples from patients treated with immunotherapy were examined for RNLS expression by quantitative immunofluorescence. Results: RNLS KO mice injected with wild-type melanoma cells reject their tumours, support -ing the importance of RNLS in cells in the TME. This effect was blunted by anti-cluster of differentiation 3. However, M & Oslash;-specific RNLS ablation was insufficient to abrogate tumour formation. Anti-RNLS antibody treatment of melanoma-bearing mice resulted in enhanced T cell infiltration and activation and resulted in immune memory on rechallenging mice with injection of melanoma cells. At the single-cell level, treatment with anti-RNLS antibodies resulted in increased tumour density of M & Oslash;, neutrophils and lymphocytes and increased expression of IFNg and granzyme B in natural killer cells and T cells. Intratumoural Fork head Box P3 CD4 cells were decreased. In two distinct murine melanoma models, we showed that melanoma-bearing mice treated with anti-RNLS antibodies plus anti-PD-1 had superior tumour shrinkage and survival than with either treatment alone. Importantly, in pretreatment samples from patients treated with PD-1 inhibitors, high RNLS expression was associated with decreased survival (log-rank P Z 0.006), independent of other prognostic variables. Conclusions: RNLS KO results in melanoma tumour regression in a T-cell-dependent fashion. Anti-RNLS antibodies enhance anti-PD-1 activity in two distinct aggressive murine melanoma models resistant to PD-1 inhibitors, supporting the development of anti-RNLS antibodies with PD-1 inhibitors as a novel approach for melanomas poorly responsive to anti PD-1. (c) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).